| scholarly article | Q13442814 |
| P50 | author | Celine Valant | Q56938593 |
| Michael Lew | Q67255069 | ||
| Patrick M. Sexton | Q39936838 | ||
| P2093 | author name string | Nathan E Hall | |
| Karen J Gregory | |||
| Arthur Christopoulos | |||
| Peter J Scammells | |||
| P2860 | cites work | Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands | Q57838214 |
| Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors | Q58856387 | ||
| Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors | Q71750189 | ||
| Structure-activity relationships among a series of acetylenic carbamates related to McN-A343 | Q72223060 | ||
| Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors | Q72827310 | ||
| Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies | Q73222968 | ||
| Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists | Q77212417 | ||
| An unusual type of sympathetic ganglionic stimulant | Q79003706 | ||
| Functional Selectivity and Classical Concepts of Quantitative Pharmacology | Q22242288 | ||
| High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor | Q24657484 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Crystal structure of rhodopsin: A G protein-coupled receptor | Q27625972 | ||
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function | Q27919659 | ||
| Qualitative and quantitative assessment of relative agonist efficacy | Q28142282 | ||
| Dimethylsulfonium analogues of the muscarinic agent McN-A-343: [4-[[N-(3- or 4-halophenyl)carbamoyl]oxy]-2-butynyl] dimethylsulfonium perchlorates | Q28339969 | ||
| Structural diversity of G protein-coupled receptors and significance for drug discovery | Q29616716 | ||
| Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins | Q30421728 | ||
| G protein-coupled receptor allosterism and complexing | Q34523552 | ||
| Seven-transmembrane receptors: crystals clarify | Q34552623 | ||
| The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart | Q36097563 | ||
| Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox | Q36556801 | ||
| Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. | Q36880915 | ||
| N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity | Q37089832 | ||
| Drugs from emasculated hormones: the principle of syntopic antagonism | Q38360052 | ||
| Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. | Q40152913 | ||
| Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site | Q40924610 | ||
| Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. | Q42277559 | ||
| Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting approach | Q42920913 | ||
| International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. | Q45345827 | ||
| Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists | Q46427567 | ||
| Allosteric binding sites on muscarinic acetylcholine receptors | Q46720566 | ||
| Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M2 receptors | Q46887583 | ||
| Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. | Q51797215 | ||
| Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. | Q52233618 | ||
| Allosteric Modulation of G Protein–Coupled Receptors | Q56115675 | ||
| P433 | issue | 43 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | G protein-coupled receptor | Q38173 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 29312-29321 | |
| P577 | publication date | 2008-08-22 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand | |
| P478 | volume | 283 |
| Q48136609 | A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy. |
| Q50896283 | A muscarinic view on Gq. |
| Q28245604 | A new mechanism of allostery in a G protein-coupled receptor dimer |
| Q93498538 | Acetylcholine (muscarinic) |
| Q37589701 | Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. |
| Q36836367 | Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. |
| Q37773480 | Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential |
| Q35952381 | Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery |
| Q37360436 | Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders |
| Q37416470 | Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. |
| Q38082089 | Approaches for probing allosteric interactions at 7 transmembrane spanning receptors |
| Q38209355 | Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective. |
| Q28468325 | Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors |
| Q34167310 | Bitopic ligands: all-in-one orthosteric and allosteric |
| Q51266726 | Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1. |
| Q59791974 | Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines |
| Q39222571 | Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode |
| Q37618780 | Cholinergic functioning in stimulant addiction: implications for medications development |
| Q35967903 | Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors |
| Q89834875 | Current Advances in Allosteric Modulation of Muscarinic Receptors |
| Q34180510 | Design strategies for bivalent ligands targeting GPCRs |
| Q60910349 | Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease |
| Q37025888 | Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits |
| Q36742217 | Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). |
| Q39772838 | Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways |
| Q27006721 | Drugs for allosteric sites on receptors |
| Q37374483 | Effects of asparagine mutagenesis of conserved aspartic acids in helix 2 (D2.50) and 3 (D3.32) of M1-M4 muscarinic receptors on the irreversible binding of nitrogen mustard analogs of acetylcholine and McN-A-343. |
| Q38125563 | Emerging paradigms in GPCR allostery: implications for drug discovery |
| Q64072003 | Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines |
| Q93551696 | G Protein-Coupled Receptors |
| Q33748133 | Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias |
| Q34124866 | Investigating the interaction of McN-A-343 with the M muscarinic receptor using its nitrogen mustard derivative and ACh mustard |
| Q33625600 | Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative |
| Q35666067 | Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists |
| Q37381371 | Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M3 receptors |
| Q34244869 | Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties |
| Q59221232 | M-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition |
| Q58856223 | M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease |
| Q38066121 | Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors |
| Q37608542 | Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor. |
| Q30498538 | Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties |
| Q34140989 | Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor |
| Q52684297 | Muscarinic M5 receptors modulate ethanol seeking in rats. |
| Q38218059 | Muscarinic acetylcholine receptors: novel opportunities for drug development |
| Q34310107 | Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343 |
| Q24653995 | N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists |
| Q28081112 | Novel Allosteric Modulators of G Protein-coupled Receptors |
| Q34399823 | Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders |
| Q37784750 | Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. |
| Q38028545 | Pharmacophore models for GABA(A) modulators: implications in CNS drug discovery |
| Q37880053 | Progress in structure based drug design for G protein-coupled receptors |
| Q37688232 | Rational design of dualsteric GPCR ligands: quests and promise |
| Q37674601 | Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist |
| Q33890786 | Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery |
| Q36347742 | Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor |
| Q33911197 | Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. |
| Q24595276 | Structural model of ligand-G protein-coupled receptor (GPCR) complex based on experimental double mutant cycle data: MT7 snake toxin bound to dimeric hM1 muscarinic receptor |
| Q27677433 | Structure and dynamics of the M3 muscarinic acetylcholine receptor |
| Q27679153 | Structure of the δ-opioid receptor bound to naltrindole |
| Q46582575 | Structure-Based Design and Discovery of New M2 Receptor Agonists |
| Q30460392 | Targeting glutamate synapses in schizophrenia |
| Q39221109 | Targeting multiple opioid receptors - improved analgesics with reduced side effects? |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q34297570 | The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling |
Search more.